Tags : Junshi Biosciences

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study

Tuba Khan September 30, 2020

Shots: The P-III Jupiter-02 Study involve assessing of Toripalimab vs PBO in combination with + Gemcitabine/ Cisplatin for 1L treatment of 289 patients with recurrent or metastatic NPC The study […]readmore

Tags : Junshi Biosciences

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Junshi Biosciences

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company